Suntou-gun, Japan

Kazuki Asanome

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Kyowa Hakko Kirin Co., Limited. Active years: 2009.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kazuki Asanome. Retrieved from https://idiyas.com/inventor/kazuki-asanome

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0



Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2009

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kazuki Asanome: Innovator in Pharmaceutical Formulations

Introduction

Kazuki Asanome is a notable inventor based in Sunto-gun, Japan. He has made significant contributions to the field of pharmaceutical formulations, particularly through his innovative work on microcrystals.

Latest Patents

Kazuki Asanome holds a patent for microcrystals of (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione. This invention features microcrystals with an average particle size of less than 50 µm, which possess excellent solubility, stability, bioavailability, and dispersing properties in pharmaceutical formulations. The patent also includes a solid pharmaceutical formulation characterized by comprising these microcrystals.

Career Highlights

Kazuki Asanome is associated with Kyowa Hakko Kirin Co., Limited, where he has been instrumental in advancing pharmaceutical technologies. His work has led to the development of formulations that enhance the effectiveness of medications.

Collaborations

Kazuki has collaborated with notable colleagues such as Kazutoshi Kuroda and Noboru Aoki, contributing to various projects that aim to improve pharmaceutical products.

Conclusion

Kazuki Asanome's innovative work in microcrystal technology has the potential to significantly impact the pharmaceutical industry. His contributions reflect a commitment to enhancing drug formulations and improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…